According to Ryman Healthcare's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 12.0181. At the end of 2022 the company had a P/E ratio of 6.25.
Year | P/E ratio | Change |
---|---|---|
2022 | 6.25 | -61.63% |
2021 | 16.3 | -20.78% |
2020 | 20.6 | 19.31% |
2019 | 17.2 | 43% |
2018 | 12.0 | 11.72% |
2017 | 10.8 | -15.73% |
2016 | 12.8 | -6.39% |
2015 | 13.7 | -16.35% |
2014 | 16.3 | 16.08% |
2013 | 14.1 | 42.49% |
2012 | 9.88 | -0.03% |
2011 | 9.88 | -16.5% |
2010 | 11.8 | -2.77% |
2009 | 12.2 | 27.73% |
2008 | 9.53 | -60.34% |
2007 | 24.0 | 22.82% |
2006 | 19.6 | 38.78% |
2005 | 14.1 | 27.11% |
2004 | 11.1 | 12.45% |
2003 | 9.86 | -37.61% |
2002 | 15.8 | 13.72% |
2001 | 13.9 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.